Separately, hypermethylation of promoters, including RASSF1A, was found to be indicative of increased risk of breast cancer: present in 70% of benign breast tissues from women at high risk (Gail risk index ≥ 2) compared with 29% of women at low/intermediate risk [63]. Here, RASSF1 is linked to breast carcinoma.